# Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery

> **NCT00887861** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 37 (actual)

## Conditions studied

- Seizures
- Epilepsy

## Interventions

- **DRUG:** Investigational new drug, company code: BGG492
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00887861
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2017-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00887861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00887861, "Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00887861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*